Data/hora: 02/06/2024 08:26:50

Provedor de dados: | Brazilian Journal of Medical and Biological Research
País: | Brazil
Título: | Erythropoietin reduces the expression of myostatin in mdx dystrophic mice
Autores: | Feder,D.; Rugollini,M.; Santomauro Jr,A.; Oliveira,L.P.; Lioi,V.P.; dos Santos,R.; Ferreira,L.G.; Nunes,M.T.; Carvalho,M.H.; Delgado,P.O.; Carvalho,A.A.S.; Fonseca,F.L.A.
Data: | 2014-11-01
Ano: | 2014
Palavras-chave: | Muscular dystrophy; Erythropoietin; Myostatin; Skeletal muscle; Quadriceps.
Resumo: | Erythropoietin (EPO) has been well characterized as a renal glycoprotein hormone regulating red blood cell production by inhibiting apoptosis of erythrocyte progenitors in hematopoietic tissues. EPO exerts regulatory effects in cardiac and skeletal muscles. Duchenne muscular dystrophy is a lethal degenerative disorder of skeletal and cardiac muscle. In this study, we tested the possible therapeutic beneficial effect of recombinant EPO (rhEPO) in dystrophic muscles in mdx mice. Total strength was measured using a force transducer coupled to a computer. Gene expression for myostatin, transforming growth factor-β1 (TGF-β1), and tumor necrosis factor-α (TNF-α) was determined by quantitative real time polymerase chain reaction. Myostatin expression was significantly decreased in quadriceps from mdx mice treated with rhEPO (rhEPO=0.60±0.11, control=1.07±0.11). On the other hand, rhEPO had no significant effect on the expression of TGF-β1 (rhEPO=0.95±0.14, control=1.05±0.16) and TNF-α (rhEPO=0.73±0.20, control=1.01±0.09). These results may help to clarify some of the direct actions of EPO on skeletal muscle.
Tipo: | Info:eu-repo/semantics/article
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2014001100966
Editor: | Associação Brasileira de Divulgação Científica
Relação: | 10.1590/1414-431X20143858
Formato: | text/html
Fonte: | Brazilian Journal of Medical and Biological Research  v.47 n.11 2014
Fonte: | info:eu-repo/semantics/openAccess